Skip to main content

Advertisement

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Fig. 3

Melanoma patients who responded to anti-CTLA-4 therapy had higher frequencies of memory T cells in baseline PBMC. CyTOF data from baseline PBMC of melanoma patients treated with anti-CTLA-4. Frequencies of (a) CD45RA+ cells in CD4+ and CD8+ T cell compartments; (b) CD45RA cells in CD4+ and CD8+ T cell compartments. c-f Memory subsets of CD4+ and CD8+ T cells in responders versus non-responders. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RACCR7+) CD4+ T cells. d Frequencies of Effector Memory (Tem, CD45RACCR7) and Terminal Effector (Teff, CD45RA+CCR7) CD4+ T cells. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RACCR7+) CD8+ T cells. d Frequencies of Effector Memory (Tem, CD45RACCR7) and Terminal Effector (Teff, CD45RA+CCR7) CD8+ T cells. *p < 0.05; **p < 0.01

Back to article page